THE Solid lipid nanoparticles A review
Abstract
Solid lipid nanoparticles are novel drug delivery system its to improve the solubility and bioavailability of the drug it has been proved that SLN is more effective colloidal drug delivery system because of it is more controlled and targeting properties, the SLN as colloidal drug carriers for incorporating hydrophilic or lipophilic drugs, the bioacceptable and biodegradable nature of SLN makes them less toxic as compared to polymeric nanoparticles, it has several potential applications in drug delivery, clinical medicine and research as well as in other varied science, in this present review this new approach is discussed in terms of their method of preparations, applications, advantages, characterization and other special features ,the SLN may open new therapy to treat difficult diseases like complex.
Keywords: solid lipid nanoparticles, drug released, method of preparations.
Downloads
Download data is not yet available.
References
1. Mukherjee S, Ray S, Thakur RS, Ind. J. Pharm. Sci., 2009; 349-358.
2. Jaiswal P, Kesharwani S, Kesharwani R, Patel D, Ethosome: A New Technology Used As Topical & Transdermal Delivery System. Journal of Drug Delivery and Therapeutics, 2016; 6(3):7-17.
3. Muller RH, Mader K, Gohla S, Eur. J. Pharm. Biopharm., 2000; 50(1):161-177.
4. Souza LG, Silva EJ, Martins AL et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm., 2011; 79(1):189-196.
5. Zhang C, Peng F, Jiangling WL et al. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int J of Nanomedicine, 2014; 9:1049-1063.
6. Ochekpe NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery. Trop J of Pharm Res., 2009; 8(3):275-287. 24
7. Wolfgang Mehnart and Karsten Mader, Adv. Drug. Deliv. Rev., 2001; 47:165-196.
8. Houli Li, Xiaobin Zhao, Yukun Ma and Guangxi Zhai, Ling Bing Li and Hong Xiang, Lou. J. Cont. Release, 2009; 133:238-244.
9. Melike Uner, Gulgun Yener, Int. J. Nanomedicine, 2007; 2(3):289-300.
10. Annette Zur Mehlen, Cora Schwarz and Wolfgang Mehnart, Eur. J. Pharm. Biopharm., 1998; 45:149-155.
11. Elena Ugazia, Roberta Cavalli and M. R. Gasco, Int. J. Pharm., 2002; 241:341-344.
12. Kaur IP, Bhandari R, Bhandari S, Kakkur. J. Cont. Rel., 2008; 127:97-109.
13. Abdelbary G, Fahmy RH, AAPS Pharm. Sci. Tech., 2009’10(1).
14. Al-Haj N, Rasedee A, Int. J. Pharmacol., 2009; 5(1):90-93.
15. Dong Zhi Hou, Chang Sheng Xie, Kaijn Huang and Chang Hong Zhu, Biomaterials, 2003; 24:1781-1785.
16. Alessandro Bargoni, Roberto Cavalla, Otto Caputo and M. R Gasco, Pharm. Res., 1998; 15(5):745-750.
17. Milan Stuchlík and Stanislav Žák, Biomed, Papers, 2001; 145(2):17-26.
18. Olbrich C, Muller RH, Int. J. Pharm., 1999; 180:31-39.
19. Schwarz D, Mehnert W, Lucks JS, Muller RH, J. Cont. Release, 1994; 30:83-96.
20. Wei Liu, Meling Hu, Wehsuang Liu and Chengbin Xue, Huibi Xu, Int. J. Pharm., 2008; 364:141-146.
21. Chena, H., et al., "Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting". Journal of Controlled Release, 2006; 110(2):296-306.
22. Wolff, K. and R.A. Johnson, "Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology, 6th edn. Part III—Diseases due to microbial agents". 2009, New York: McGraw-Hill.
23. Maia C.S., Mehnert W, and Schaller M, "Drug targeting by solid lipid nanoparticles for dermal use". Journal of Drug Targeting, 2002; 10:489-495.
24. ERK N., Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography. J. Chromatogr. B., v.784, n.1, p.195201, 2003.
25. Ganapuram B.R.; Alle M.; Dadigala R.; Kotu G.M.; Guttena V. Development, evaluation and characterization of surface solid dispersion for solubility and dispersion enhancement of irbesartan. J. Pharm. Res., 2013; 7(6):472-477.
26. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. International journal of pharmaceutics. 2008; 355(12):307-313.
27. Li X, Nie Sf, Kong J, Li N, Ju CY, Pan WS. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008; 363(1-2):177-182.
28. Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm. 2011; 403(1-2):185191.
29. Vishvakrama P, Sharma S, Liposomes: An Overview. Journal of Drug Delivery and Therapeutics, 2014; 47-55.
30. Mehnert W, Mäder K. Solid lipid nanoparticles-production, characterization and applications. Advanced drug delivery reviews, 2001; 47:165–196.
31. Jawahar N, Meyyanathan SN, Reddy G, Sood S. Solid lipid nanoparticles for oral delivery of poorly soluble drugs.Journal of pharmaceutical science and research. 2012; 4(7):1848-1855.
32. Shah DP, Patel B, Shah C, Nanosuspension technology: A innovative slant for drug delivery system and permeability enhancer for poorly water soluble drugs, Journal of Drug Delivery and Therapeutics, 2015; 5(1):10-23
33. Yadav N, Khatak S, Sara UVS. Solid lipid nanoparticles- a review. International journal applied p’ceutics, 2013; 5(2):818
2. Jaiswal P, Kesharwani S, Kesharwani R, Patel D, Ethosome: A New Technology Used As Topical & Transdermal Delivery System. Journal of Drug Delivery and Therapeutics, 2016; 6(3):7-17.
3. Muller RH, Mader K, Gohla S, Eur. J. Pharm. Biopharm., 2000; 50(1):161-177.
4. Souza LG, Silva EJ, Martins AL et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm., 2011; 79(1):189-196.
5. Zhang C, Peng F, Jiangling WL et al. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int J of Nanomedicine, 2014; 9:1049-1063.
6. Ochekpe NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery. Trop J of Pharm Res., 2009; 8(3):275-287. 24
7. Wolfgang Mehnart and Karsten Mader, Adv. Drug. Deliv. Rev., 2001; 47:165-196.
8. Houli Li, Xiaobin Zhao, Yukun Ma and Guangxi Zhai, Ling Bing Li and Hong Xiang, Lou. J. Cont. Release, 2009; 133:238-244.
9. Melike Uner, Gulgun Yener, Int. J. Nanomedicine, 2007; 2(3):289-300.
10. Annette Zur Mehlen, Cora Schwarz and Wolfgang Mehnart, Eur. J. Pharm. Biopharm., 1998; 45:149-155.
11. Elena Ugazia, Roberta Cavalli and M. R. Gasco, Int. J. Pharm., 2002; 241:341-344.
12. Kaur IP, Bhandari R, Bhandari S, Kakkur. J. Cont. Rel., 2008; 127:97-109.
13. Abdelbary G, Fahmy RH, AAPS Pharm. Sci. Tech., 2009’10(1).
14. Al-Haj N, Rasedee A, Int. J. Pharmacol., 2009; 5(1):90-93.
15. Dong Zhi Hou, Chang Sheng Xie, Kaijn Huang and Chang Hong Zhu, Biomaterials, 2003; 24:1781-1785.
16. Alessandro Bargoni, Roberto Cavalla, Otto Caputo and M. R Gasco, Pharm. Res., 1998; 15(5):745-750.
17. Milan Stuchlík and Stanislav Žák, Biomed, Papers, 2001; 145(2):17-26.
18. Olbrich C, Muller RH, Int. J. Pharm., 1999; 180:31-39.
19. Schwarz D, Mehnert W, Lucks JS, Muller RH, J. Cont. Release, 1994; 30:83-96.
20. Wei Liu, Meling Hu, Wehsuang Liu and Chengbin Xue, Huibi Xu, Int. J. Pharm., 2008; 364:141-146.
21. Chena, H., et al., "Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting". Journal of Controlled Release, 2006; 110(2):296-306.
22. Wolff, K. and R.A. Johnson, "Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology, 6th edn. Part III—Diseases due to microbial agents". 2009, New York: McGraw-Hill.
23. Maia C.S., Mehnert W, and Schaller M, "Drug targeting by solid lipid nanoparticles for dermal use". Journal of Drug Targeting, 2002; 10:489-495.
24. ERK N., Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography. J. Chromatogr. B., v.784, n.1, p.195201, 2003.
25. Ganapuram B.R.; Alle M.; Dadigala R.; Kotu G.M.; Guttena V. Development, evaluation and characterization of surface solid dispersion for solubility and dispersion enhancement of irbesartan. J. Pharm. Res., 2013; 7(6):472-477.
26. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. International journal of pharmaceutics. 2008; 355(12):307-313.
27. Li X, Nie Sf, Kong J, Li N, Ju CY, Pan WS. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008; 363(1-2):177-182.
28. Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm. 2011; 403(1-2):185191.
29. Vishvakrama P, Sharma S, Liposomes: An Overview. Journal of Drug Delivery and Therapeutics, 2014; 47-55.
30. Mehnert W, Mäder K. Solid lipid nanoparticles-production, characterization and applications. Advanced drug delivery reviews, 2001; 47:165–196.
31. Jawahar N, Meyyanathan SN, Reddy G, Sood S. Solid lipid nanoparticles for oral delivery of poorly soluble drugs.Journal of pharmaceutical science and research. 2012; 4(7):1848-1855.
32. Shah DP, Patel B, Shah C, Nanosuspension technology: A innovative slant for drug delivery system and permeability enhancer for poorly water soluble drugs, Journal of Drug Delivery and Therapeutics, 2015; 5(1):10-23
33. Yadav N, Khatak S, Sara UVS. Solid lipid nanoparticles- a review. International journal applied p’ceutics, 2013; 5(2):818
Statistics
245 Views | 323 Downloads
How to Cite
1.
Patil P, Harak K, Saudagar R. THE Solid lipid nanoparticles A review. JDDT [Internet]. 15May2019 [cited 22Jan.2021];9(3):525-30. Available from: http://jddtonline.info/index.php/jddt/article/view/2773
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.